

Drugs - Real World Outcomes

Real-World Treatment Patterns Among Pediatric and Adult Patients with Crohn's Disease in the United States

Art Kastl, M.D.¹, Theresa Hunter Gible, Ph.D., MPH, M.S.², Debbie Tinsley, B.S.², Wallace V. Crandall, M.D., MMM², Wendy J. Komocsar, B.S.², Yu Du, MPH², Casey K. Choong, Ph.D.², Payal Jha, Ph.D.², Wai Man Maria Chan, PharmD, MPH^{2}*

¹Children's Hospital of Philadelphia, Philadelphia, USA

²Eli Lilly and Company, Indianapolis, USA

Supplementary material


Supplementary Table 1. Initial combination therapy among pediatric and adult patients with CD

	Overall		Newly diagnosed		Previously diagnosed	
	Pediatric cohort (N=2,809)	Adult cohort (N=25,940)	Pediatric cohort (N=1,675)	Adult cohort (N=12,961)	Pediatric cohort (N=1,134)	Adult cohort (N=12,979)
Aminosalicylates + Corticosteroids, n (%)	200 (22.0)	1,223 (31.5)	183 (28.6)	908 (50.6)	17 (6.3)	315 (15.1)
Biologics + Immunomodulators, n (%)	124 (13.6)	599 (15.4)	29 (4.5)	96 (5.4)	95 (35.3)	503 (24.1)
Biologics + Corticosteroids, n (%)	190 (20.9)	561 (14.4)	170 (26.6)	244 (13.6)	20 (7.4)	317 (15.2)
Aminosalicylates + Immunomodulators, n (%)	84 (9.2)	497 (12.8)	22 (3.4)	145 (8.1)	62 (23.1)	352 (16.8)
Corticosteroids + Immunomodulators, n (%)	174 (19.1)	459 (11.8)	151 (23.6)	255 (14.2)	23 (8.6)	204 (9.8)
Aminosalicylates + Biologics, n (%)	35 (3.9)	234 (6.0)	12 (1.9)	50 (2.8)	23 (8.6)	184 (8.8)
Biologics + Corticosteroids + Immunomodulators, n (%)	33 (3.6)	112 (2.9)	28 (4.4)	36 (2.0)	5 (1.9)	76 (3.6)
Aminosalicylates + Corticosteroids + Immunomodulators, n (%)	45 (5.0)	80 (2.1)	36 (5.6)	37 (2.1)	9 (3.4)	43 (2.1)
Aminosalicylates + Biologics + Corticosteroids, n (%)	12 (1.3)	63 (1.6)	8 (1.3)	21 (1.2)	4 (1.5)	42 (2.0)
Aminosalicylates + Biologics + Immunomodulators, n (%)	9 (1.0)	48 (1.2)	1 (0.2)	2 (0.1)	8 (3.0)	46 (2.2)
Aminosalicylates + Biologics + Corticosteroids +	3 (0.3)	9 (0.2)	-	1 (0.1)	3 (1.1)	8 (0.4)


Immunomodulators, n (%)						
CD=Crohn's disease; N=total number of patients.						

Supplementary Figure 1. Overview of medication regimen usage

a) During 1-year follow-up




b) During 3-year follow-up



Medication prescribed to patients over the 1- and 3-year follow-up periods was not mutually exclusive. Over 50% of patients received a combination of therapies.

Supplementary Figure 2. Use of biologics

a) During 1-year follow-up



b) During 3-year follow-up

